Kristen D. Onos

Kristen D. Onos

Auto-generated profile, based on publicly available information

Kristen D. Onos

The Jackson Laboratory, Bar Harbor, ME USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2018 in Brain
Verified
Journal Article
Open access
PDF file
CTChad A Tagge
Chad A Tagge
AFAndrew M Fisher
Andrew M Fisher
OMOlga V Minaeva
Olga V Minaeva
AGAmanda Gaudreau-Balderrama
Amanda Gaudreau-Balderrama
JMJuliet A Moncaster
Juliet A Moncaster
LGLee E Goldstein
Lee E Goldstein
The mechanisms underpinning concussion, traumatic brain injury, and chronic traumatic encephalopathy, and the relationships between these disorders, are poorly understood. We examined post-mortem brains from teenage athletes in the acute-subacute period after mild closed-head impact injury and found astrocytosis, myelinated axonopathy, microvascular injury, perivascular neuroinflammation, and phosphorylated tau protein pathology. To investigate causal mechanisms, we developed a mouse model of lateral closed-head impact injury that uses momentum transfer to induce traumatic head acceleration. Unanaesthetized mice subjected to unilateral impact exhibited abrupt onset, transient course, and rapid resolution of a concussion-like syndrome characterized by altered arousal, contralateral hemiparesis, truncal ataxia, locomotor and balance impairments, and neurobehavioural deficits. Experimental impact injury was associated with axonopathy, blood–brain barrier disruption, astrocytosis, microgliosis (with activation of triggering receptor expressed on myeloid cells, TREM2), monocyte infiltration, and phosphorylated tauopathy in cerebral cortex ipsilateral and subjacent to impact. Phosphorylated tauopathy was detected in ipsilateral axons by 24 h, bilateral axons and soma by 2 weeks, and distant cortex bilaterally at 5.5 months post-injury. Impact pathologies co-localized with serum albumin extravasation in the brain that was diagnostically detectable in living mice by dynamic contrast-enhanced MRI. These pathologies were also accompanied by early, persistent, and bilateral impairment in axonal conduction velocity in the hippocampus and defective long-term potentiation of synaptic neurotransmission in the medial prefrontal cortex, brain regions distant from acute brain injury. Surprisingly, acute neurobehavioural deficits at the time of injury did not correlate with blood–brain barrier disruption, microgliosis, neuroinflammation, phosphorylated tauopathy, or electrophysiological dysfunction. Furthermore, concussion-like deficits were observed after impact injury, but not after blast exposure under experimental conditions matched for head kinematics. Computational modelling showed that impact injury generated focal point loading on the head and seven-fold greater peak shear stress in the brain compared to blast exposure. Moreover, intracerebral shear stress peaked before onset of gross head motion. By comparison, blast induced distributed force loading on the head and diffuse, lower magnitude shear stress in the brain. We conclude that force loading mechanics at the time of injury shape acute neurobehavioural responses, structural brain damage, and neuropathological sequelae triggered by neurotrauma. These results indicate that closed-head impact injuries, independent of concussive signs, can induce traumatic brain injury as well as early pathologies and functional sequelae associated with chronic traumatic encephalopathy. These results also shed light on the origins of concussion and relationship to traumatic brain injury and its aftermath.

1 April 2016 in Brain Research Bulletin
Verified
Journal Article
Open access
KOKristen D. Onos
Kristen D. Onos
SRStacey J. Sukoff Rizzo
Stacey J. Sukoff Rizzo
GHGareth R. Howell
Gareth R. Howell
MSMichael Sasner
Michael Sasner
Genetic mouse models for Alzheimer's disease (AD) have been widely used to understand aspects of the biology of the disease, but have had limited success in translating these findings to the clinic. In this review, we discuss the benefits and limitations of existing genetic models and recent advances in technologies (including high throughput sequencing and genome editing) that promise more predictive models. We summarize widely used biomarkers and behavioral tests for mouse models of AD and highlight best practices that will maximize translatability of preclinical findings.

31 May 2019 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
KOKristen D. Onos
Kristen D. Onos
AUAsli Uyar
Asli Uyar
KKKelly J. Keezer
Kelly J. Keezer
HJHarriet M. Jackson
Harriet M. Jackson
CPChristoph Preuss
Christoph Preuss
GHGareth R. Howell
Gareth R. Howell
Classical laboratory strains show limited genetic diversity and do not harness natural genetic variation. Mouse models relevant to Alzheimer’s disease (AD) have largely been developed using these classical laboratory strains, such as C57BL/6J (B6), and this has likely contributed to the failure of translation of findings from mice to the clinic. Therefore, here we test the potential for natural genetic variation to enhance the translatability of AD mouse models. Two widely used AD-relevant transgenes, APPswe and PS1de9 (APP/PS1), were backcrossed from B6 to three wild-derived strains CAST/EiJ, WSB/EiJ, PWK/PhJ, representative of three Mus musculus subspecies. These new AD strains were characterized using metabolic, functional, neuropathological and transcriptional assays. Strain-, sex- and genotype-specific differences were observed in cognitive ability, neurodegeneration, plaque load, cerebrovascular health and cerebral amyloid angiopathy. Analyses of brain transcriptional data showed strain was the greatest driver of variation. We identified significant variation in myeloid cell numbers in wild type mice of different strains as well as significant differences in plaque-associated myeloid responses in APP/PS1 mice between the strains. Collectively, these data support the use of wild-derived strains to better model the complexity of human AD. Despite the rise in incidence of Alzheimer’s disease (AD), it has been over a decade since a new drug treatment has been introduced. Recently, a number of pharmaceutical giants have shut down their AD research units. One issue that these companies and researchers have struggled with is the lack of translatability of preclinical studies to the clinic. One aspect that has come under heavy scrutiny is whether the mouse can be an appropriate model for a complex human disease such as AD. Current mouse models of AD have incorporated well-known early onset AD mutations on a single genetic background, C57BL/6J, which does not develop all features of human AD- namely marked neurodegeneration. Here we sought to improve the utility and translatability of mouse models through the use of three genetically distinct, wild-derived inbred mouse strains, CAST/EiJ, WSB/EiJ and PWK/PhJ. These mice encompass millions of genetic differences that have never before been explored in the context of modeling AD. Wild-derived mice that carried the early onset AD mutations exhibited robust differences in immune response to amyloid, evidence of mixed pathology and early neurodegeneration, better recapitulating what happens in human AD than previous models.

3 May 2011 in Hippocampus
Verified
Journal Article
Closed access
PDF file
JHJacqueline R. Hembrook
Jacqueline R. Hembrook
KOKristen D. Onos
Kristen D. Onos
RMRobert Mair
Robert Mair

1 February 2021 in Cell Reports
Verified
Journal Article
Open access
HYHongtian Stanley Yang
Hongtian Stanley Yang
KOKristen D. Onos
Kristen D. Onos
KCKwangbom Choi
Kwangbom Choi
KKKelly J. Keezer
Kelly J. Keezer
DSDaniel A. Skelly
Daniel A. Skelly
GHGareth R. Howell
Gareth R. Howell
Genetic and genome-wide association studies suggest a central role for microglia in Alzheimer's disease (AD). However, single-cell RNA sequencing (scRNA-seq) of microglia in mice, a key preclinical model, has shown mixed results regarding translatability to human studies. To address this, scRNA-seq of microglia from C57BL/6J (B6) and wild-derived strains (WSB/EiJ, CAST/EiJ, and PWK/PhJ) with and without APP/PS1 demonstrates that genetic diversity significantly alters features and dynamics of microglia in baseline neuroimmune functions and in response to amyloidosis. Results show significant variation in the abundance of microglial subtypes or states, including numbers of previously identified disease-associated and interferon-responding microglia, across the strains. For each subtype, significant differences in the expression of many genes are observed in wild-derived strains relative to B6, including 19 genes previously associated with human AD including Apoe, Trem2, and Sorl1. This resource is critical in the development of appropriately targeted therapeutics for AD and other neurological diseases.

20 August 2010 in Dose-Response
Verified
Journal Article
Open access
RMRobert Mair
Robert Mair
KOKristen D. Onos
Kristen D. Onos
JHJacqueline R. Hembrook
Jacqueline R. Hembrook
Central thalamus regulates forebrain arousal, influencing activity in distributed neural networks that give rise to organized actions during alert, wakeful states. Central thalamus has been implicated in working memory by the effects of lesions and microinjected drugs in this part of the brain. Lesions and drugs that inhibit neural activity have been found to impair working memory. Drugs that increase activity have been found to enhance and impair memory depending on the dose tested. Electrical deep brain stimulation (DBS) similarly enhances working memory at low stimulating currents and impairs it at higher currents. These effects are time dependent. They were observed when DBS was applied during the memory delay (retention) or choice response (retrieval) but not earlier in trials during the sample (acquisition) phase. The effects of microinjected drugs and DBS are consistent with the Yerkes-Dodson law, which describes an inverted-U relationship between arousal and behavioral performance. Alternatively these results may reflect desensitization associated with higher levels of stimulation, spread of drugs or current to adjacent structures, or activation of less sensitive neurons or receptors at higher DBS currents or drug doses.